Loading page...
Loading page...
This round is closed. The next round and similar open calls are listed below. Synced from the EU Funding & Tenders Portal on 9 November 2026.
This call is closed. These open or upcoming calls fund the closest work.
Based on projects the EU funded on the same subject in this programme.
IMPROVAe-Intervention Enhancing Mental Health in Adolescents
HORIZON-HLTH-2022-STAYHLTH-01-01-two-stage · 2023 · Official record ↗
YOUTHreachBridging Gaps in Mental Health Support: A Comprehensive European Strategy
HORIZON-HLTH-2024-DISEASE-03-08-two-stage · 2025 · Official record ↗
EQUICARESCommunity-driven Healthcare Access and Mental Health Promotion for Inclusive, Equitable, and Resilient European Societies
HORIZON-HLTH-2024-CARE-04-04-two-stage · 2025 · Official record ↗
ADVANCEADDRESSING MENTAL HEALTH VULNERABILITIES FROM ADOLESCENCE TO OLDER AGE: INNOVATING PREVENTION SCIENCE FOR TIMES OF CHANGE
HORIZON-HLTH-2022-STAYHLTH-01-01-two-stage · 2023 · Official record ↗
ASP-belongAugmented Social Play (ASP): smartphone-enabled group psychotherapeutic interventions that boost adolescent mental health by supporting real-world connection and sense of belonging
HORIZON-HLTH-2022-STAYHLTH-01-01-two-stage · 2023 · Official record ↗
BootstrapBoosting Societal Adaptation and Mental Health in a Rapidly Digitalizing, Post-Pandemic Europe
HORIZON-HLTH-2022-STAYHLTH-01-01-two-stage · 2023 · Official record ↗
MENTBESTProtecting mental health in times of change
HORIZON-HLTH-2022-STAYHLTH-01-01-two-stage · 2023 · Official record ↗
M-CAREImplementation of an Integrated Care Model for Patients with Multiple Cardiometabolic and Mental Health Conditions in Sub-Saharan Africa
HORIZON-HLTH-2024-DISEASE-13-01 · 2025 · Official record ↗
Each one links to its EU funding record and the partners it works with: a starting list for building a consortium.
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:
Already before the COVID-19 pandemic, 1 in 6 people in the EU suffered from mental health issues. The economic costs of it are estimated at 4% of the Gross Domestic Product (GDP)[2] and since then these figures worsened[3] in particular among vulnerable groups such as children and adolescents or those at risk of discrimination. Digital technologies have the potential to enhance mental health for instance by providing access to information, support networks and therapy services[4]. However, there are indications that the excessive or misguided use of digital technologies, particularly among children and young adults, can negatively affect mental health and exacerbate mental disorders. There is an urgent need for more robust data to foster a safer, responsible and healthier use of digital technologies among children and young adults, prioritising the protection of their mental health.
Therefore, proposals should aim at generating robust scientific evidence on the impact of digital technologies, as well as developing and testing context-specific digital interventions that promote the positive and responsible use of them to improve mental health, avoiding the development or exacerbation of mental disorders. These innovative digital interventions should leverage multi-source data (e.g. sleep patterns, heart rate, stress levels, screen-time analytics, social media use, biological data, clinical data), and could include the use of Artificial Intelligence (AI). When handling data and indicators, sex and gender identity-disaggregated data should be collected and analysed, incorporating intersectional factors where feasible.
The applicants should address all the following aspects:
The topic is open to address any mental disorder[5] caused or aggravated by the use of digital technologies such as addiction, self-harm behaviour, increased anxiety or decreased self-esteem, sleeping-disorders, post-traumatic stress disorders.
Cohort studies and clinical studies are in the scope for this topic. Applicants envisaging to include longitudinal cohort studies are invited to indicate a sustainability plan on how those cohorts are maintained over an extended period beyond the end period of the project for a long-term follow-up. They should make use of existing cohorts data when available. Applicants are welcome to consider recruiting participants transnationally and from diverse settings in the clinical study design to ensure generalizability of findings. In addition, it should be detailed in the proposal how the proposed intervention(s) could be scaled-up and transferred to other settings. Applicants should also consider the inclusion of end-users in the codesign of the interventions, for example for the young age groups, this includes the involvement of families, carers, educators. Applicants should access and make best-use of already existing European Research Infrastructures relevant for brain-research (e.g. EBRAINS[6], Euro-BioImaging[7]).
All projects funded under this topic should liaise with relevant European projects on mental health[8] and the future co-funded European Partnership for Brain Health[9]. They are also encouraged to explore potential synergies with projects to be funded under the EU4Health Work Programme 2026 related to the harmful effects of using digital technologies on the mental health of children and young adults.
The participation of start-ups and/or micro, small and medium-sized enterprises (SMEs)[10] is encouraged with the aim to strengthen their scientific and technological basis and valorise their innovations and to advance commercial exploitation.
Proposals should adhere to the FAIR[11] data principles, adopt wherever relevant, data standards and data sharing/access good practices, and apply good practices for GDPR[12] compliant personal data protection.
The topic requires the effective contribution of social sciences and humanities (SSH) disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities. The support and involvement of citizens and civil society should be considered.
Applicants should provide details of their clinical studies[13] in the dedicated annex using the template provided in the submission system. As proposals under this topic are expected to include clinical studies, the use of the template is strongly encouraged.
[1] There is no universal definition of youth and young adults. For the purpose of this topic, we follow the WHO definition of young adult a person aged 15-24: https://www.who.int/southeastasia/health-topics/adolescent-health
[2] https://health.ec.europa.eu/system/files/2020-02/2018_healthatglance_rep_en_0.pdf
[3] https://www.europarl.europa.eu/RegData/etudes/BRIE/2023/751416/EPRS_BRI(2023)751416_EN.pdf
[4] https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52023DC0298
[5] ICD11, Chapter 6: https://icd.who.int/browse/2025-01/mms/en#334423054
[6] https://www.ebrains.eu
[7] https://www.eurobioimaging.eu
[8] Projects funded under topics HORIZON-HLTH-2024-STAYHLTH-01-02-two-stage: "Towards a holistic support to children and adolescents’ health and care provisions in an increasingly digital society" and HORIZON-HLTH-2022-STAYHLTH-01-01-two-stage: "Boosting mental health in Europe in times of change".
[9] https://www.brainhealth-partnership.eu
[10] https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32003H0361
[11] See definition of FAIR data in the introduction to this Work Programme part.
[12] General Data Protection Regulation: https://commission.europa.eu/law/law-topic/data-protection_en, https://gdpr-info.eu
[13] Please note that the definition of clinical studies (see introduction to this Work Programme part) is broad and it is recommended that you review it thoroughly before submitting your application.
1. Admissibility Conditions, proposal page limit and layout
Admissibility conditions are described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Proposal page limits and layout are described in Part B of the Application Form available in the Submission System.
2. Eligible Countries
Eligible countries are described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
3. Other Eligibility Conditions
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.
If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).
Subject to restrictions for the protection of European communication networks.
Other eligibility conditions are described in Annex B of the Work Programme General Annexes.
4. Financial and operational capacity and exclusion
Financial and operational capacity and exclusion are described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes.
5b. Evaluation and award: Submission and evaluation processes
The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12.
Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual.
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
Indicative timeline for evaluation and grant agreement are described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants
The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.
Legal and financial set-up of the grants are described in Annex G of the Work Programme General Annexes.
Specific conditions are described in the specific topic of the Work Programme.
Application and evaluation forms and additional documents:
Application and evaluation form templates
Standard application form (HE RIA, IA) - the application form specific to this call is available in the Submission System
Standard evaluation form (HE RIA, IA) - will be used with the necessary adaptations
Guidance
HE Programme Guide
Model Grant Agreement (MGA)
HE MGA
Call-specific instructions 
Information on clinical studies (HE)
Additional documents
HE Main Work Programme 2026-2027 – 1. General Introduction
HE Main Work Programme 2026-2027 – 4. Health
HE Main Work Programme 2026-2027 – 15. General Annexes
HE Programme Guide
HE Framework Programme 2021/695
HE Specific Programme Decision 2021/764
EU Financial Regulation 2024/2509
Decision authorising the use of lump sum contributions under the Horizon Europe Programme
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual
Funding & Tenders Portal Terms and Conditions
Funding & Tenders Portal Privacy Statement
Applicants asked the EU 4 questions about this call and the EU published the answers. They clarify the call documents but do not replace them.
The protection of European communication networks has been identified as an important security interest of the Union and its Member States. For further details, you are advised to refer to the introduction of the destination under which this topic falls (as found in the Health Cluster work programme part for 2026-27).
Read it on the EU portal ↗Answered 7 Oct 2026
No, this topic is not using the Lump Sum funding model.
Read it on the EU portal ↗Answered 2 Nov 2026
Please note that the definition of clinical studies, together with additional useful information can be found in the introduction of Health Cluster Work Programme part for 2026-2027.
Additionally, we would like to bring to your attention the fact that the World Health Organization (WHO) has published a “Guidance for best practices for clinical trials”. You are not required not follow this guidance, however we encourage you to do so.
Finally, we would also like to encourage you to consider the latest innovations and advances in the clinical trial design and research methods in order to evaluate promising interventions allowing shorter development timings.
Read it on the EU portal ↗Answered 28 Jun 2026
The Health Cluster Work Programme part for 2026-2027 includes a “right to object” condition for nearly all topics, giving the granting authority the right to object to a transfer of ownership or to the exclusive licensing of results, up to 4 years after the end of the action.
For applicants and beneficiaries, little is expected to change, as in previous years this condition had been part of the General Annexes, having legal force across all parts of Horizon Europe (including the Health Cluster topics). In practise, the granting authority may invoke the “right to object” under specific conditions, which so far has happened in very rare occasions over the many years of Horizon Europe.
More details below from Annex 5 of the General Model Grant Agreement:
Where the call conditions in Horizon Europe actions provide for the right to object to transfers or licensing, the granting authority may — up to four years after the end of the action — object to a transfer of ownership or the exclusive licensing of results, if:
the beneficiaries which generated the results have received funding under the grant
it is to a legal entity established in a non-EU country not associated with Horizon Europe, and
the granting authority considers that the transfer or licence is not in line with EU interests.
Beneficiaries that intend to transfer ownership or grant an exclusive licence must formally notify the granting authority before the intended transfer or licensing takes place and:
identify the specific results concerned
describe in detail the new owner or licensee and the planned or potential exploitation of the results, and
include a reasoned assessment of the likely impact of the transfer or licence on EU interests, in particular regarding competitiveness as well as consistency with ethical principles and security considerations.
The granting authority may request additional information.
If the granting authority decides to object to a transfer or exclusive licence, it must formally notify the beneficiary concerned within 60 days of receiving notification (or any additional information it has requested).
No transfer or licensing may take place in the following cases:
pending the granting authority decision, within the period set out above
if the granting authority objects
until the conditions are complied with, if the granting authority objection comes with conditions.
A beneficiary may formally notify a request to waive the right to object regarding intended transfers or grants to a specifically identified third party, if measures safeguarding EU interests are in place. If the granting authority agrees, it will formally notify the beneficiary concerned within 60 days of receiving notification (or any additional information requested).
Read it on the EU portal ↗Answered 28 Jun 2026
Confirm the current call documents and submission conditions with the funding authority.
View on EU portal ↗Source: EU Funding & Tenders Portal · synced 2026-11-09
A free account keeps your shortlist and sends deadline reminders. The EUACC connector brings this call, its FAQs, past winners and similar calls into Claude or ChatGPT, so you can check fit and draft with sources.